Aeluma Q3 EPS $0.00 Up From $(0.06) YoY, Sales $1.25M Up From $343.89K YoY

0.00% Pre

Aeluma Inc Ordinary Shares

ALMU

0.00

Aeluma (NASDAQ: ALMU) reported $1.25 million in sales this quarter. This is a 264.93 percent increase over sales of $343.89 thousand the same period last year.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Ohio Rep. David Taylor Bought Over $7K Worth of Home Depot Stock: Here's What You Should Know

Pegatron Chair Calms Taiwan Semiconductor Leak Drama, Says Chip Rivalry Can't Steal Its Edge

B of A Securities Maintains Buy on Seagate Technology Hldgs, Raises Price Target to $320

Jim Cramer: This Communication Services Stock Is 'Too Speculative'

Dell's AI Infrastructure Upgrade 'Project Maverick' Faces Delays Amid Scalability Concerns: Report

Walmart, Intuit, The Gap, SanDisk And Moderna: Why These 5 Stocks Are On Investors' Radars Today

Stock Ratings | HC Wainwright & Co. maintained its "buy" rating on Cullinan Therapeutics (CGEM) and raised its price target from $24 to $26, representing a potential upside of 198.17%.

OpenAI Teams Up With Foxconn To Design And Manufacture AI Hardware In The US